Assuntos
Espru Colágeno/diagnóstico , Mucosa Intestinal/patologia , Corticosteroides/uso terapêutico , Colágeno/química , Espru Colágeno/complicações , Espru Colágeno/terapia , Colonoscopia , Diarreia/complicações , Dieta Livre de Glúten , Endoscopia , Evolução Fatal , Hospitalização , Humanos , Imunoglobulina A/imunologia , Masculino , Pessoa de Meia-Idade , Tumores Neuroendócrinos/diagnóstico , Fumar/efeitos adversos , Tomografia Computadorizada por Raios X , Resultado do Tratamento , UltrassonografiaRESUMO
Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis. While it has been speculated that collagenous enteritis represents a form of refractory celiac disease, recent clinical studies suggest a potential link to exposure to the antihypertensive medication olmesartan. Here we hypothesized that the pathogenesis of collagenous enteritis involves both genetic and environmental factors. All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications, smoking history, demographics, histology, clinical management, and follow-up were recorded. A total of 32 subjects were included. In contrast to celiac disease, subjects with collagenous enteritis were mostly elderly (median age at diagnosis, 69 y; range, 33 to 84 y). Seventy percent of collagenous enteritis subjects harbored celiac disease susceptibility alleles HLA-DQ2/DQ8; however, only 1 subject had elevated serum levels of celiac disease-associated autoantibodies while on a gluten-containing diet. Furthermore, 56% of subjects were taking nonsteroidal anti-inflammatory drugs, 36% proton-pump inhibitors, 28% statins, and 32% olmesartan at the time of diagnosis. Discontinuation of olmesartan and treatments with steroids and/or gluten-free diet resulted in symptomatic and histologic improvement. Neither lymphoma nor collagenous enteritis-related death was seen in this cohort. Therefore, while collagenous enteritis shares similar HLA genotypes with celiac disease, the difference in demographics, the lack of celiac disease-associated autoantibodies, and potential link to medications as environmental triggers suggest the 2 entities are likely distinct in pathogenesis.
Assuntos
Doença Celíaca/genética , Colágeno/análise , Espru Colágeno/genética , Enterite/genética , Antígenos HLA-DQ/genética , Intestino Delgado/química , Adulto , Idoso , Idoso de 80 Anos ou mais , Bloqueadores do Receptor Tipo 1 de Angiotensina II/efeitos adversos , Biópsia , Doença Celíaca/classificação , Doença Celíaca/imunologia , Doença Celíaca/patologia , Espru Colágeno/classificação , Espru Colágeno/metabolismo , Espru Colágeno/terapia , Dieta Livre de Glúten , Enterite/classificação , Enterite/metabolismo , Enterite/terapia , Feminino , Predisposição Genética para Doença , Antígenos HLA-DQ/imunologia , Humanos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/patologia , Masculino , Pessoa de Meia-Idade , Missouri , Pennsylvania , Fenótipo , Estudos Retrospectivos , Fatores de Risco , Esteroides/uso terapêutico , Resultado do TratamentoRESUMO
BACKGROUND: Collagenous sprue (CS) is a rare form of enteropathy that had been reported to be associated with celiac disease (CD) and collagenous colitis (CC). The aim of our study was to compare the clinical features, treatments, and outcomes of CS, CD, and CC. METHODS: All patients with histologic diagnosis of CS, CD, or CC with complete clinical data were extracted from our pathology database between 1990 and 2015. Demographic and clinical features were recorded along with treatments and outcomes. RESULTS: A total of 21 patients with CS were included. Overall CS patients were more symptomatic with 17 (81.0%) patients with diarrhea and 15 (71.4%) with unintentional weight loss. Positive celiac serology was noted in 5 (23.8%) CS patients. CS patients had higher rates for disease-related temporary total parenteral nutrition (TPN) use (38.1% vs. 1.1% vs. 1.0%, P < 0.0001) and disease-related hospitalization (52.4% vs. 3.3% vs. 8.2%, P < 0.0001) than that in CD and CC patients. Twenty CS patients received treatments, including the combination of gluten-free diet (GFD) and corticosteroids (n = 12), GFD only (n = 2), and corticosteroids only (n = 6). All CS patients showed symptomatic reliefs with treatment. Although CS patients had a higher rate for hospitalization and TPN use, disease-related death was not observed in all three groups. CONCLUSIONS: Collagenous sprue patients had more severe clinical presentation than patients with CD and CC and therefore had higher demand for temporary TPN and hospitalization. Nevertheless, a prompt use of steroids and/or GFD upon histologic diagnosis of CS may have contributed to an overall excellent prognosis.
Assuntos
Doença Celíaca , Colite Colagenosa , Espru Colágeno , Corticosteroides/uso terapêutico , Idoso , Doença Celíaca/terapia , Colite Colagenosa/terapia , Espru Colágeno/terapia , Diarreia , Dieta Livre de Glúten , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Nutrição Parenteral Total/estatística & dados numéricos , Prognóstico , Redução de PesoRESUMO
AIM: While collagenous colitis represents the most common form of the collagenous gastroenteritides, the collagenous entities affecting the proximal part of the gastrointestinal tract are much less recognized and possibly overlooked. The aim was to summarize the latest information through a systematic review of collagenous gastritis, collagenous sprue, and a combination thereof. METHOD: The search yielded 117 studies which were suitable for inclusion in the systematic review. Excluding repeated cases, 89 case reports and 28 case series were reported, whereas no prospective studies with or without control groups were identified. Further, no randomized, controlled trials were identified. The total number of patients with proximal collagenous gastroenteritides reported was 330. RESULTS: An overview of clinical presentations, prognosis, pathophysiology and histopathology, as well as management of these disorders is presented. The prognosis of both collagenous gastritis and sprue seems not to be as dismal as considered previously. Data point to involvement of immune or autoimmune mechanisms potentially driven by luminal antigens initiating the fibroinflammatory condition. CONCLUSIONS: To reach the diagnosis it is recommended that biopsies are obtained during gastroduodenoscopies. Therapies with anti-secretory strategies, glucocorticoids, and in some cases iron supplementation are suggested, although rational treatment options from randomized, controlled trials do not exist for these rare or even overlooked disorders.
Assuntos
Colite Colagenosa/fisiopatologia , Espru Colágeno/fisiopatologia , Gastroenterite/fisiopatologia , Biópsia , Colite Colagenosa/diagnóstico , Colite Colagenosa/terapia , Colágeno/metabolismo , Espru Colágeno/diagnóstico , Espru Colágeno/terapia , Endoscopia Gastrointestinal/métodos , Gastrite/diagnóstico , Gastrite/fisiopatologia , Gastrite/terapia , Gastroenterite/diagnóstico , Gastroenterite/terapia , Glucocorticoides/uso terapêutico , Humanos , Compostos de Ferro/uso terapêutico , PrognósticoRESUMO
Double balloon endoscopy (DBE) is useful for diagnosing many intestinal diseases and for endoscopic procedures. We report a case of chronic diarrhea in a 58-year-old Japanese man. He was initially suspected to have malabsorption syndrome. DBE showed reduction of folds, scalloping, mucosal nodularity and granularity. Pathological examinations of biopsies from the jejunum showed severe villous atrophy with subepithelial collagen bands. These findings led to the final diagnosis of collagenous sprue (CS). With1 month of total parenteral nutrition followed by a low-gluten diet, his symptoms gradually improved. CS has never been reported before in Japan. DBE is useful for making a diagnosis of CS, and may be considered for patients who are suffering from diarrhea of unknown cause.
Assuntos
Espru Colágeno/diagnóstico , Endoscopia por Cápsula , Colágeno/metabolismo , Espru Colágeno/dietoterapia , Espru Colágeno/terapia , Dieta Livre de Glúten , Enteroscopia de Duplo Balão , Humanos , Imuno-Histoquímica , Jejuno/patologia , Masculino , Pessoa de Meia-Idade , Nutrição Parenteral , Tomografia Computadorizada por Raios XRESUMO
Collagenous sprue (CS) is a pattern of small-bowel injury characterized histologically by marked villous blunting, intraepithelial lymphocytes, and thickened sub-epithelial collagen table. Clinically, patients present with diarrhea, abdominal pain, malabsorption, and weight loss. Gluten intolerance is the most common cause of villous blunting in the duodenum; however, in a recent case series by the Mayo Clinic, it has been reported that olmesartan can have a similar effect. In this case report, a 62-year-old female with a history of hypothyroidism and hypertension managed for several years with olmesartan presented with abdominal pain, weight loss, and nausea. Despite compliance to a gluten-free diet, the patient's symptoms worsened, losing 20 pounds in 3 wk. Endoscopy showed thickening, scalloping, and mosaiform changes of the duodenal mucosa. The biopsy showed CS characterized by complete villous atrophy, lymphocytosis, and thickened sub-epithelial collagen table. After 2 mo cessation of olmesartan, the patient's symptoms improved, and follow-up endoscopy was normal with complete villous regeneration. These findings suggest that olmesartan was a contributing factor in the etiology of this patient's CS. Clinicians should be aware of the possibility of drug-induced CS and potential reversibility after discontinuation of medication.